tacedinaline
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Aug 1, 1997 (NCT00005624)
Timeline
Indications
Mechanism of action
- Histone deacetylaseINHIBITOR
Histone deacetylase inhibitor
- Histone deacetylase 1 (HDAC1) ↗
- Histone deacetylase 3 (HDAC3) ↗
- Histone deacetylase 6 (HDAC6) ↗
- Histone deacetylase 2 (HDAC2) ↗
- Histone deacetylase 5 (HDAC5) ↗
- Histone deacetylase 7 (HDAC7) ↗
- Histone deacetylase 8 (HDAC8) ↗
- Histone deacetylase 11 (HDAC11) ↗
- Histone deacetylase 4 (HDAC4) ↗
- Histone deacetylase 9 (HDAC9) ↗
- Histone deacetylase 10 (HDAC10) ↗
- Histone deacetylase 8
- Histone deacetylase 10
- Histone deacetylase 2
- Histone deacetylase 3
- Histone deacetylase 4
- Histone deacetylase 6
- Histone deacetylase 9
- Histone deacetylase 11
- Histone deacetylase 5
- Histone deacetylase 7
- Histone deacetylase 1
- Histone deacetylase (HDAC1 and HDAC2)
- Histone deacetylase 1/3/5/8
- Histone deacetylase 1/2/3/6
- Histone deacetylase 1/2/3
- Histone deacetylase 1/8
- Histone deacetylase 1/6
- Class 1 histone deacetylase
- Histone deacetylase 6/3
Chemistry & pharmacology
Loading structure…
SMILES
CC(=O)Nc1ccc(C(=O)Nc2ccccc2N)cc1- Mol. weight
- 269.3 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL235191 ↗
Also known as
- 4-acetylamino-n-(2'-aminophenyl)benzamide
- acetyldinaline
- ci 994
- ci-994
- ci-994
- ci-994
- ci-994
- goe 5549
- goe-5549
- goe-5549
- goe-5549
- pd 123654
- pd-123654
- pd-123654
- pd-123654
- tacedinaline
- tacedinaline
- tacedinaline
- tacedinaline
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00005093 | Phase 3 | Dec 1, 1999 | Pfizer |
| NCT00004861 | Phase 2 | Oct 1, 1999 | Pfizer |
| NCT00005624 | Phase 2 | Aug 1, 1997 | National Cancer Institute (NCI), Parke-Davis, University of South Florida |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 2 | 2 | 2 | 1999 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 1997 |
| Parke-Davis | For profit | 1 | 0 | 1 | 1997 |
| University of South Florida | Academic/Hospital | 1 | 1 | 1 | 1997 |
4 organizations
Page 1 / 1